Pelthos Therapeutics (PTHS) FCF Margin (2025 - 2026)

Pelthos Therapeutics (PTHS) posted quarterly FCF Margin of 37.89% for Q4 2025, up 99.27% quarter-over-quarter from 5190.04% in Q3 2025.

Pelthos Therapeutics (PTHS) FCF Margin (2025 - 2026) Analysis & Trends

Pelthos Therapeutics' FCF Margin history runs 1 years deep, the most recent figure standing at 37.89% for Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	30.39%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	13.35%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-388.28%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	25.68%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	22.62%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-22.35%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	70.82%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	41.07%
10	Pelthos Therapeutics	96.56 Mn	72.00 Mn	21.23 Mn	-79.17%

Download Data